JP2022515158A5 - - Google Patents

Info

Publication number
JP2022515158A5
JP2022515158A5 JP2021535756A JP2021535756A JP2022515158A5 JP 2022515158 A5 JP2022515158 A5 JP 2022515158A5 JP 2021535756 A JP2021535756 A JP 2021535756A JP 2021535756 A JP2021535756 A JP 2021535756A JP 2022515158 A5 JP2022515158 A5 JP 2022515158A5
Authority
JP
Japan
Prior art keywords
disorder
compound according
disorders
pain
addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515158A (ja
JP7649743B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068109 external-priority patent/WO2020132605A1/en
Publication of JP2022515158A publication Critical patent/JP2022515158A/ja
Publication of JP2022515158A5 publication Critical patent/JP2022515158A5/ja
Priority to JP2024195978A priority Critical patent/JP2025024045A/ja
Application granted granted Critical
Publication of JP7649743B2 publication Critical patent/JP7649743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535756A 2018-12-21 2019-12-20 有機化合物 Active JP7649743B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195978A JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783618P 2018-12-21 2018-12-21
US62/783,618 2018-12-21
PCT/US2019/068109 WO2020132605A1 (en) 2018-12-21 2019-12-20 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195978A Division JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Publications (3)

Publication Number Publication Date
JP2022515158A JP2022515158A (ja) 2022-02-17
JP2022515158A5 true JP2022515158A5 (https=) 2022-12-14
JP7649743B2 JP7649743B2 (ja) 2025-03-21

Family

ID=71101940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535756A Active JP7649743B2 (ja) 2018-12-21 2019-12-20 有機化合物
JP2024195978A Withdrawn JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195978A Withdrawn JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Country Status (4)

Country Link
US (2) US12331052B2 (https=)
EP (1) EP3897621A4 (https=)
JP (2) JP7649743B2 (https=)
WO (1) WO2020132605A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
WO2020131899A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
US12195463B2 (en) 2018-12-21 2025-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) * 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
CA3134674A1 (en) * 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
MX2024004725A (es) * 2021-10-19 2024-05-10 Intra Cellular Therapies Inc Metodos novedosos.
CN119343348A (zh) * 2022-03-14 2025-01-21 细胞内治疗公司 有机化合物
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) * 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
CN119930620A (zh) * 2024-02-05 2025-05-06 和径医药科技（上海）有限公司 四并环类化合物、其制备方法、药物组合物及应用
WO2025257090A1 (en) 2024-06-10 2025-12-18 Interquim, S.A. Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
SK7042003A3 (en) 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
CA2580619C (en) 2004-09-20 2013-11-12 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
JP4912320B2 (ja) 2004-12-07 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換された四環式テトラヒドロピラン、ピロリジンおよびテトラヒドロチオフェン誘導体
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
NZ586963A (en) 2008-02-05 2012-11-30 Clera Inc Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP5773781B2 (ja) * 2011-06-30 2015-09-02 株式会社東芝 超音波診断装置、画像処理装置及びプログラム
EP3153149B1 (en) 2011-08-16 2018-04-11 Tosho, Inc. Tablet splitting apparatus
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AR092568A1 (es) 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US20200392135A1 (en) 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
PL3497104T3 (pl) 2016-08-09 2022-02-21 Teva Pharmaceuticals International Gmbh Postacie w stanie stałym soli ditosylanowej lumateperonu
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
US20210008065A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP3833346A4 (en) 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
WO2020131899A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
US12195463B2 (en) 2018-12-21 2025-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
CA3134674A1 (en) 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
JP7397095B2 (ja) 2019-05-07 2023-12-12 ニーサム・ラボラトリーズ・インコーポレイテッド オピオイド受容体アンタゴニストプロドラッグ
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
CN117425652A (zh) 2021-06-07 2024-01-19 细胞内治疗公司 新盐和晶体
MX2024004725A (es) 2021-10-19 2024-05-10 Intra Cellular Therapies Inc Metodos novedosos.

Similar Documents

Publication Publication Date Title
JP2022515158A5 (https=)
US8017631B2 (en) Oxadiazole derivatives and their medical use
RU2018130727A (ru) Органические соединения
JP2021519267A5 (https=)
JP6505023B2 (ja) Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
TWI224102B (en) Serotonergic agents
JP2008540637A5 (https=)
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина
RU2016140266A (ru) Спироциклические аминовые производные в качестве модуляторов s1p
EP2324007A1 (en) Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
JP2009538910A5 (https=)
JP2019163256A (ja) イミダゾピリダジン化合物
RU2008110911A (ru) Новые диазабициклические арильные производные и их медицинское применение
CN108884093B (zh) 一种多巴胺d3配体化合物
JP2007520539A5 (https=)
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез
JP2021529813A (ja) チアジアジン誘導体
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の（１，４−ジアザ−ビシクロ［３．２．２］ノン−６−エン−４−イル）−ヘテロシクリル−メタノンリガンド
CN102015697B (zh) 酰胺衍生物以及含有该酰胺衍生物的药物组合物
CN100534983C (zh) 环胺衍生物、其制备方法以及包含该化合物的药物组合物
CN115427409B (zh) 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
CN1276921C (zh) 5－(吡啶－3－基)－1－氮杂二环[3.2.1]辛烷衍生物,其制备及其治疗应用
JP2012509860A5 (https=)
JP2007523207A5 (https=)
JP2006519251A5 (https=)